心脏代谢标准作为代谢功能障碍相关脂肪性肝病中肝脏相关事件和心血管事件的预测因素和治疗目标
这项全国性人群研究纳入979,352例MASLD患者,发现基线心脏代谢标准数量增多与主要不良心血管事件(MACE)累积发生率升高相关,而与肝脏相关事件无关。纵向分析中,以基线5项标准且无改善者为参照,标准改善越多MACE风险越低,但标准改善与肝脏相关事件无显著关联。
要点
- 基线心脏代谢标准数量越多,MACE累积发生率越高,但肝脏相关事件无此趋势。
- 以5项标准无改善为参照,改善至4、3、2、0-1项标准的MACE调整HR分别为0.55、0.20、0.13、0.06。
- 心脏代谢标准改善与肝脏相关事件风险无显著关联。
核心结论
- 心脏代谢标准可作为MASLD中心血管事件风险的预测因素和治疗目标。
- 开发肝脏相关事件的预测因素和治疗目标是未来的挑战。
研究设计与样本
- 全国性、基于人群的研究,纳入979,352例MASLD患者。
- 分析基线心脏代谢标准数量与肝脏相关事件或MACE风险的关系。
- 另进行纵向分析,纳入基线具有5项标准者,分析1年后标准改善与并发症发生率的关系。
主要发现
- MACE累积发生率随基线心脏代谢标准数量增加而升高,肝脏相关事件无此趋势。
- 纵向多变量分析以5项标准(无改善)为参照,MACE的调整HR(95%CI):4项标准0.55(0.52-0.58,p<0.001),3项标准0.20(0.17-0.22,p<0.001),2项标准0.13(0.11-0.16,p<0.001),0-1项标准0.06(0.02-0.3,p<0.001)。
- 随着心脏代谢标准改善,MACE风险降低。
- 心脏代谢标准改善与肝脏相关事件无显著关联。
关键数值与推荐
- MASLD诊断要求至少满足五项心脏代谢标准中的一项。
- 纵向分析中,以基线5项标准且无改善为参照,改善至4项标准者MACE的调整HR为0.55(95%CI 0.52-0.58,p<0.001)。
- 改善至3项标准者MACE的调整HR为0.20(95%CI 0.17-0.22,p<0.001)。
- 改善至2项标准者MACE的调整HR为0.13(95%CI 0.11-0.16,p<0.001)。
- 改善至0-1项标准者MACE的调整HR为0.06(95%CI 0.02-0.3,p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) requires at least one of five cardiometabolic criteria. It is unclear whether these criteria can be used as predictors and treatment targets for complications including liver-related events and major adverse cardiovascular events (MACE). AIMS: To investigate the relationship between cardiometabolic criteria and complications. METHODS: We conducted a nationwide, population-based study of 979,352 patients with MASLD. We investigated relationships between a number of criteria at baseline and liver-related events or MACE risks. In a separate longitudinal analysis, we included patients with five criteria at baseline and investigated the relationship between improving the criteria and the incidence of complications after 1 year. RESULTS: The cumulative incidence of MACE, but not liver-related events, increased with increasing baseline cardiometabolic criteria. In the longitudinal study, multivariable analysis using patients with five criteria (no improvement) as the reference, adjusted hazard ratios (95% confidence interval) of MACE in patients with 4, 3, 2, and 0-1 criteria (1 to 4-5 criteria improvement) were 0.55 (0.52-0.58, p < 0.001), 0.20 (0.17-0.22, p < 0.001), 0.13 (0.11-0.16, p < 0.001), and 0.06 (0.02-0.3, p < 0.001), respectively. The risk of MACE decreased as the cardiometabolic criteria improved. There was no significant association between improvement of the criteria and liver-related events. CONCLUSIONS: Cardiometabolic criteria can be used as predictors and treatment targets for cardiovascular event risk in MASLD. Developing predictors and therapeutic targets for liver-related events is a future challenge.
引用
- Tamaki N, Kimura T, Wakabayashi SI, et al. Cardiometabolic criteria as predictors and treatment targets of liver-related events and cardiovascular events in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024. PMID: 39115116. doi:10.1111/apt.18205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。